Oragenics (OGEN) Competitors $0.12 -0.01 (-8.61%) As of 02:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock OGEN vs. XFOR, RLMD, GLYC, BFRG, PMN, CING, ALLR, GOVX, FLGC, and TRIBShould you be buying Oragenics stock or one of its competitors? The main competitors of Oragenics include X4 Pharmaceuticals (XFOR), Relmada Therapeutics (RLMD), GlycoMimetics (GLYC), Bullfrog AI (BFRG), ProMIS Neurosciences (PMN), Cingulate (CING), Allarity Therapeutics (ALLR), GeoVax Labs (GOVX), Flora Growth (FLGC), and Trinity Biotech (TRIB). These companies are all part of the "pharmaceutical products" industry. Oragenics vs. X4 Pharmaceuticals Relmada Therapeutics GlycoMimetics Bullfrog AI ProMIS Neurosciences Cingulate Allarity Therapeutics GeoVax Labs Flora Growth Trinity Biotech X4 Pharmaceuticals (NASDAQ:XFOR) and Oragenics (NYSE:OGEN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability, earnings and community ranking. Which has higher valuation & earnings, XFOR or OGEN? Oragenics has lower revenue, but higher earnings than X4 Pharmaceuticals. Oragenics is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioX4 Pharmaceuticals$31.36M0.62-$101.17M$2.141.57Oragenics$40K64.96-$20.66M-$1.12-0.11 Which has more risk & volatility, XFOR or OGEN? X4 Pharmaceuticals has a beta of 0.73, meaning that its share price is 27% less volatile than the S&P 500. Comparatively, Oragenics has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500. Is XFOR or OGEN more profitable? X4 Pharmaceuticals' return on equity of -236.19% beat Oragenics' return on equity.Company Net Margins Return on Equity Return on Assets X4 PharmaceuticalsN/A -236.19% -75.14% Oragenics N/A -2,087.95%-486.56% Do analysts prefer XFOR or OGEN? X4 Pharmaceuticals currently has a consensus price target of $72.33, indicating a potential upside of 2,055.99%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe X4 Pharmaceuticals is more favorable than Oragenics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score X4 Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Oragenics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community favor XFOR or OGEN? X4 Pharmaceuticals received 80 more outperform votes than Oragenics when rated by MarketBeat users. Likewise, 68.38% of users gave X4 Pharmaceuticals an outperform vote while only 0.00% of users gave Oragenics an outperform vote. CompanyUnderperformOutperformX4 PharmaceuticalsOutperform Votes8068.38% Underperform Votes3731.62% OragenicsOutperform VotesNo VotesUnderperform Votes55100.00% Does the media favor XFOR or OGEN? In the previous week, X4 Pharmaceuticals and X4 Pharmaceuticals both had 1 articles in the media. X4 Pharmaceuticals' average media sentiment score of 1.89 beat Oragenics' score of 0.00 indicating that X4 Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment X4 Pharmaceuticals Very Positive Oragenics Neutral Do insiders & institutionals have more ownership in XFOR or OGEN? 72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 18.7% of Oragenics shares are owned by institutional investors. 2.4% of X4 Pharmaceuticals shares are owned by company insiders. Comparatively, 4.9% of Oragenics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryX4 Pharmaceuticals beats Oragenics on 11 of the 16 factors compared between the two stocks. Get Oragenics News Delivered to You Automatically Sign up to receive the latest news and ratings for OGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OGEN vs. The Competition Export to ExcelMetricOragenicsPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$2.60M$6.54B$5.39B$19.35BDividend YieldN/A2.64%5.28%3.90%P/E Ratio-0.028.6926.9934.46Price / Sales64.96235.34403.1238.78Price / CashN/A65.8538.2517.51Price / Book0.206.286.744.70Net Income-$20.66M$143.71M$3.23B$1.02B7 Day Performance-36.32%0.45%0.69%0.75%1 Month Performance-34.88%-0.74%6.29%4.45%1 Year Performance-94.05%-0.70%19.55%5.43% Oragenics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OGENOragenicsN/A$0.12-8.6%N/A-93.3%$2.60M$40,000.00-0.025XFORX4 Pharmaceuticals4.3801 of 5 stars$2.92flat$72.33+2,377.2%-87.4%$16.90M$31.36M-32.4480Positive NewsGap DownRLMDRelmada Therapeutics4.7637 of 5 stars$0.51+10.4%$4.25+735.0%-75.4%$16.90MN/A-0.1810Short Interest ↓GLYCGlycoMimetics1.6705 of 5 stars$0.26+5.2%N/A-16.9%$16.77M$10,000.00-0.5650News CoverageBFRGBullfrog AI1.7255 of 5 stars$1.74-0.6%N/A-34.7%$16.38M$60,000.00-2.054Positive NewsShort Interest ↓PMNProMIS Neurosciences3.1755 of 5 stars$0.50-2.7%$4.50+800.0%-72.6%$16.34MN/A-5.005Short Interest ↓CINGCingulate2.8751 of 5 stars$3.81-0.3%$25.75+575.9%+477.7%$16.18MN/A-0.4520Analyst ForecastShort Interest ↓ALLRAllarity Therapeutics0.5468 of 5 stars$1.07+2.9%N/A-95.0%$16.14MN/A0.0010Short Interest ↓GOVXGeoVax Labs3.3064 of 5 stars$1.02+3.6%$11.10+988.2%-39.2%$15.50M$5.59M-0.2810Short Interest ↓FLGCFlora Growth3.2223 of 5 stars$0.67-1.6%$4.00+501.5%-45.2%$15.25M$53.26M-0.68280Positive NewsTRIBTrinity Biotech1.673 of 5 stars$0.82-3.2%N/A-60.5%$14.80M$59.13M-0.36480Positive NewsShort Interest ↓ Related Companies and Tools Related Companies X4 Pharmaceuticals Competitors Relmada Therapeutics Competitors GlycoMimetics Competitors Bullfrog AI Competitors ProMIS Neurosciences Competitors Cingulate Competitors Allarity Therapeutics Competitors GeoVax Labs Competitors Flora Growth Competitors Trinity Biotech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:OGEN) was last updated on 5/30/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump Just Gave the Green Light to Rewrite Social Security?In a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredHISTORIC Gold Move Sends Flashing Red Signal To 401K SaversHistorically, when panic hits Wall Street, investors rush to raise cash to cover their leveraged positions be ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oragenics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oragenics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy OGEN Stock Free OGEN Stock Alerts